The U.K.'s Vectura has thrown its dry powder inhaler technology into a newly established Chinese joint venture biotech that is setting out to develop and commercialize new respiratory treatments for a growing Asian market.
Stat Research, a Buenos Aires-based CRO, has reached out to eClinical provider Datatrak in an effort to reduce clinical trial costs and accelerate drug development timelines.
GlaxoSmithKline is turning to market-expansion contractors DKSH to push its antibiotic products in Hong Kong, part of the drugmaker's efforts to cash in on booming Asian demand.
Bristol-Myers Squibb will collaborate with Adaptive Biotechnologies to develop immunological biomarkers for cancer, representing another step forward in the development of personalized medicine.
Elan has struck a deal to pay a billion dollars for a share of Theravance's future royalties on Breo and a slate of other respiratory drugs now in development, announcing the deal right on the heels of Breo's approval in the U.S. on Friday.
With its lead drug poised to begin a Phase IIb study for acute heart failure, Trevena grabbed a $30 million investment from Forest Laboratories, which also picked up an option to snag global rights to the biotech's lead therapy with a deal that includes a $430 million potential payout.
Shire has nailed down another deal to fuel its growing rare disease unit. The pharma group has tapped the Cambridge, MA-based startup Nimbus Discovery, which will use its computational approach to find small-molecule drugs for rare genetic diseases known as lysosomal storage disorders.
Insulet, creator of the OmniPod tubeless insulin pump, joined forces with Eli Lilly this week to develop a new version of the device designed to deliver Lilly's Humulin R U-500 insulin.
Just a month after landing a $15 million payday for a deal with Astellas to collaborate on new antibody drug conjugates for cancer, the San Diego-based biotech Ambrx has scored another research pact--reaping another $15 million upfront from Bristol-Myers in exchange for a new oncology partnership.
Yesterday Merck's top executives spent a considerable amount of time trying to reassure analysts that the Big Pharma company is actively engaged in the hunt for new drugs needed to beef up a weak pipeline.